NVZMF (Novonesis (Novozymes) B) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NVZMF Novonesis (Novozymes) B NVZMF
90 GF Score
Price $66.44
GF Value $63.82
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Novonesis (Novozymes) B Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Novonesis (Novozymes) B Valuation Rank Related Terms

NVZMF
90GF Score
Novonesis (Novozymes) B NVZMF
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Novonesis (Novozymes) B (NVZMF) Overvalued in 2026?

Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued. The current stock price of $66.44 is trading 4.1% above its estimated GF Value™ of $63.82. GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.

Key valuation signals for NVZMF:

  • Valuation Rank:
  • GF Value™: $63.82 vs. price of $66.44 (4.1% above fair value)
  • GF Score™: 90/100 with 5 warning signs

No single metric tells the full story. See the NVZMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novonesis (Novozymes) B Business Description

Address Krogshoejvej 36, Bagsvaerd, DNK, 2880
Novonesis (Novozymes) B is a Danish biotechnology company formed in 2024 through the merger of Novozymes and Chr. Hansen. It is a leading global producer of industrial enzymes and microbial solutions, serving industries such as household care, food and beverages, bioenergy, agriculture and animal feed, and technical and pharmaceutical applications. Its biological products help customers improve yield, efficiency, and performance while reducing energy use and waste. The company operates across two main business areas: enzymes and microorganisms, spanning food and health biosolutions and agriculture, bioenergy, and technical biosolutions. Headquartered in Denmark, Novonesis employs more than 11,000 people and operates numerous research, development, and application centers alongside manufacturing sites worldwide. Revenue is generated primarily through the sale of enzyme and microbial products to industrial and agricultural customers globally, supported by ongoing research and application development.
90GF Score

Get the complete analysis for NVZMF

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$66.44
Price
$63.82
GF Value